{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T13:42:57Z","timestamp":1794490977985,"version":"4.9.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009032","name":"Pfizer Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpeds.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pediatrics"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.jpeds.2021.05.051","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T12:32:20Z","timestamp":1622118740000},"page":"154-161.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial"],"prefix":"10.1016","volume":"237","author":[{"given":"Christine M.","family":"Pierce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min H.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9812-732X","authenticated-orcid":false,"given":"Baldvin","family":"Jonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinu","family":"Iorga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narayan","family":"Cheruvu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile C.","family":"Balagtas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin H.","family":"Steinhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpeds.2021.05.051_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1542\/peds.105.1.14","article-title":"Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes","volume":"105","author":"Walsh-Sukys","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2021.05.051_bib2","first-page":"63","article-title":"Persistent pulmonary hypertension in the newborn","volume":"4","author":"Mathew","year":"2017","journal-title":"Children (Basel)"},{"key":"10.1016\/j.jpeds.2021.05.051_bib3","first-page":"CD000399","article-title":"Nitric oxide for respiratory failure in infants born at or near term","volume":"1","author":"Barrington","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpeds.2021.05.051_bib4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.semperi.2005.02.003","article-title":"The diseases treated with ECMO: focus on PPHN","volume":"29","author":"Farrow","year":"2005","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.jpeds.2021.05.051_bib5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJM199702273360901","article-title":"Inhaled nitric oxide in full-term and nearly full-term infants with hypoxic respiratory failure","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jpeds.2021.05.051_bib6","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/CIRCRESAHA.107.161463","article-title":"Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells","volume":"102","author":"Farrow","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.jpeds.2021.05.051_bib7","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1111\/bph.14205","article-title":"PDE5 inhibitors\u2014pharmacology and clinical applications 20 years after sildenafil discovery","volume":"175","author":"Andersson","year":"2018","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jpeds.2021.05.051_bib8","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1542\/peds.2005-0523","article-title":"Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study","volume":"117","author":"Baquero","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2021.05.051_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3233\/NPM-15814137","article-title":"Outcome of oral sildenafil in neonatal persistent pulmonary hypertension of non-cardiac causes","volume":"8","author":"Sayed","year":"2015","journal-title":"J Neonatal Perinatal Med"},{"key":"10.1016\/j.jpeds.2021.05.051_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3233\/NPM-16161","article-title":"Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study","volume":"9","author":"Al Omar","year":"2016","journal-title":"J Neonatal Perinatal Med"},{"key":"10.1016\/j.jpeds.2021.05.051_bib11","first-page":"677","article-title":"Oral sildenafil use in neonates with persistent pulmonary hypertension of newborn","volume":"29","author":"Hussain","year":"2017","journal-title":"J Ayub Med Coll Abbottabad"},{"key":"10.1016\/j.jpeds.2021.05.051_bib12","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ppul.22985","article-title":"Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn","volume":"49","author":"Kahveci","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jpeds.2021.05.051_bib13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jpeds.2009.06.012","article-title":"Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension","volume":"155","author":"Steinhorn","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2021.05.051_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0029-1239496","article-title":"The use of sildenafil in persistent pulmonary hypertension of the newborn","volume":"27","author":"Vargas-Origel","year":"2010","journal-title":"Am J Perinatol"},{"key":"10.1016\/j.jpeds.2021.05.051_bib15","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/jp.2015.31","article-title":"Arterial hypotension and prerenal failure in an extremely preterm infant associated with oral sildenafil","volume":"35","author":"Balasubramanian","year":"2015","journal-title":"J Perinatol"},{"key":"10.1016\/j.jpeds.2021.05.051_bib16","first-page":"CD005494","article-title":"Sildenafil for pulmonary hypertension in neonates","volume":"8","author":"Kelly","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jpeds.2021.05.051_bib17","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.2174\/1381612811209023034","article-title":"The use of sildenafil in the treatment of persistent pulmonary hypertension of the newborn: a review of the literature","volume":"18","author":"Iacovidou","year":"2012","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jpeds.2021.05.051_bib18","doi-asserted-by":"crossref","first-page":"iii","DOI":"10.1165\/rcmb.2012-0441ED","article-title":"Beyond pulmonary hypertension: sildenafil for chronic lung disease of prematurity","volume":"48","author":"Steinhorn","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.jpeds.2021.05.051_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/2249-4847.105958","article-title":"Is sildenafil an effective therapy in the management of persistent pulmonary hypertension?","volume":"1","author":"Yaseen","year":"2012","journal-title":"J Clin Neonatol"},{"key":"10.1016\/j.jpeds.2021.05.051_bib21","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/clpt.2008.177","article-title":"Population pharmacokinetics of sildenafil in term neonates: evidence of rapid maturation of metabolic clearance in the early postnatal period","volume":"85","author":"Mukherjee","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jpeds.2021.05.051_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12890-017-0374-x","article-title":"Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension","volume":"17","author":"Vizza","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jpeds.2021.05.051_bib23","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1542\/peds.113.3.559","article-title":"A randomized trial of early versus standard inhaled nitric oxide therapy in term and near-term newborn infants with hypoxic respiratory failure","volume":"113","author":"Konduri","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.jpeds.2021.05.051_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jpeds.2006.11.065","article-title":"Early inhaled nitric oxide therapy for term and near-term newborn infants with hypoxic respiratory failure: neurodevelopmental follow-up","volume":"150","author":"Konduri","year":"2007","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2021.05.051_bib25","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/jp.2013.83","article-title":"Impact of early surfactant and inhaled nitric oxide therapies on outcomes in term\/late preterm neonates with moderate hypoxic respiratory failure","volume":"33","author":"Konduri","year":"2013","journal-title":"J Perinatol"},{"key":"10.1016\/j.jpeds.2021.05.051_bib26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.phrs.2016.04.025","article-title":"Clinical research in neonates and infants: Challenges and perspectives","volume":"108","author":"Coppini","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jpeds.2021.05.051_bib27","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.clinthera.2017.09.006","article-title":"Enrollment of neonates in more than one clinical trial","volume":"39","author":"Davis","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.jpeds.2021.05.051_bib28","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/bcp.12467","article-title":"Clinical trials of medicines in neonates: the influence of ethical and practical issues on design and conduct","volume":"79","author":"Turner","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jpeds.2021.05.051_bib29","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jamapediatrics.2015.1640","article-title":"Global collaboration to develop new and existing drugs for neonates","volume":"169","author":"Davis","year":"2015","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jpeds.2021.05.051_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jpeds.2016.06.078","article-title":"Bosentan as Adjunctive therapy for persistent pulmonary hypertension of the newborn: results of the randomized multicenter placebo-controlled exploratory trial","volume":"177","author":"Steinhorn","year":"2016","journal-title":"J Pediatr"},{"key":"10.1016\/j.jpeds.2021.05.051_bib32","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1086\/674903","article-title":"Hydrocortisone normalizes phosphodiesterase-5 activity in pulmonary artery smooth muscle cells from lambs with persistent pulmonary hypertension of the newborn","volume":"4","author":"Perez","year":"2014","journal-title":"Pulm Circ"}],"container-title":["The Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347621005023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022347621005023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:08:56Z","timestamp":1758359336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022347621005023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":30,"alternative-id":["S0022347621005023"],"URL":"https:\/\/doi.org\/10.1016\/j.jpeds.2021.05.051","relation":{},"ISSN":["0022-3476"],"issn-type":[{"value":"0022-3476","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and Safety of IV Sildenafil in the Treatment of Newborn Infants with, or at Risk of, Persistent Pulmonary Hypertension of the Newborn (PPHN): A Multicenter, Randomized, Placebo-Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpeds.2021.05.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}